Literature DB >> 2714974

Relevance of prostaglandins in true menstrual migraine.

G Nattero, G Allais, C De Lorenzo, C Benedetto, M Zonca, E Melzi, M Massobrio.   

Abstract

Eighteen patients suffering from true menstrual migraine and 12 control subjects were studied. We evaluated in different phases of the menstrual cycle and during the migraine crisis the peripheral plasma concentrations of 6-keto-PGF1 alpha (the stable metabolite of PGI2), thromboxane B2 (the stable metabolite of thromboxane A2), PGF2 alpha and PGE2. The mean values of 6-keto-PGF1 alpha in menstrual migraine sufferers are lower than in normal women throughout the whole cycle. The difference between the trends observed in the two groups is statistically significant (p less than 0.05). The plasma levels of TXB2 and of PGF2 alpha are similar in the two groups investigated, both in basal conditions and during the attack. The plasma concentrations of PGE2 are slightly lower in migraineurs in basal conditions than in normals. However, during the crisis they increase significantly (p less than 0.05). In conclusion, among all the parameters considered, PGE2 seems to play the most important role during the pain phase of the attack. The results of the present study suggest that a deficit of PGI2, one of the most important protecting agents against ischemia, might be a typical feature of menstrual migraine and might cause in these patients a vascular hypersensitivity to different ischemic stimuli.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714974     DOI: 10.1111/j.1526-4610.1989.hed22904233.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  17 in total

Review 1.  Treatment of perimenstrual migraine with triptans: an update.

Authors:  Barbara Casolla; Luana Lionetto; Serena Candela; Lidia D'Alonzo; Andrea Negro; Maurizio Simmaco; Paolo Martelletti
Journal:  Curr Pain Headache Rep       Date:  2012-10

Review 2.  Treating migraine with contraceptives.

Authors:  Gianni Allais; Giulia Chiarle; Silvia Sinigaglia; Gisella Airola; Paola Schiapparelli; Fabiola Bergandi; Chiara Benedetto
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 3.  The use of triptans in the management of menstrual migraine.

Authors:  Lisa K Mannix; Julia A Files
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Estrogen, migraine, and vascular risk.

Authors:  Gianni Allais; Giulia Chiarle; Silvia Sinigaglia; Gisella Airola; Paola Schiapparelli; Chiara Benedetto
Journal:  Neurol Sci       Date:  2018-06       Impact factor: 3.307

5.  Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium.

Authors:  Vincent T Martin; Jeanne Ballard; Michael P Diamond; Lisa K Mannix; Frederick J Derosier; Shelly E Lener; Alok Krishen; Susan A McDonald
Journal:  J Womens Health (Larchmt)       Date:  2014-02-28       Impact factor: 2.681

Review 6.  Menstrual migraine: a review of prophylactic therapies.

Authors:  Vincent T Martin
Journal:  Curr Pain Headache Rep       Date:  2004-06

7.  EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries.

Authors:  Richard J Davis; Colin E Murdoch; Mozam Ali; Stuart Purbrick; Rivka Ravid; Gordon S Baxter; Nick Tilford; Robert L G Sheldrick; Kenneth L Clark; Robert A Coleman
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 8.  Hormone-related headache: pathophysiology and treatment.

Authors:  Avi Ashkenazi; Stephen D Silberstein
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

9.  BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.

Authors:  K A Maubach; R J Davis; D E Clark; G Fenton; P M Lockey; K L Clark; A W Oxford; R M Hagan; C Routledge; R A Coleman
Journal:  Br J Pharmacol       Date:  2009-01-19       Impact factor: 8.739

10.  Frovatriptan plus dexketoprofen in the treatment of menstrually related migraine: an open study.

Authors:  Gianni Allais; Sara Rolando; Paola Schiapparelli; Gisella Airola; Paola Borgogno; Ornella Mana; Chiara Benedetto
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.